Human Chorionic Gonadotropin (HCG) | Buy Research-Grade HCG in Europe | ≥99% Purity

Human Chorionic Gonadotropin (hCG) is a naturally occurring heterodimeric glycoprotein hormone and potent luteinising hormone receptor (LH-R) agonist, available to buy in Europe for laboratory research into gonadotropin receptor pharmacology, Leydig cell biology, steroidogenesis, HPG axis regulation, luteal phase biology, and the comparative pharmacology of LH/hCG receptor signalling.

Laboratories and research institutions across the EU can order verified, research-grade hCG with fast international dispatch to Europe, full batch documentation, and ≥99% purity confirmed by HPLC and Mass Spectrometry.

✅ ≥99% Purity — HPLC & Mass Spectrometry Verified

✅ Batch-Specific Certificate of Analysis (CoA)

✅ Sterile Lyophilised Powder | GMP Manufactured

✅ Fast Dispatch to EU & Europe | Tracked Shipping

What is Human Chorionic Gonadotropin (HCG)?

Human Chorionic Gonadotropin (hCG) is a heterodimeric glycoprotein hormone of the cystine-knot growth factor superfamily, produced physiologically by syncytiotrophoblast cells of the placenta following embryo implantation. Structurally, hCG is composed of two non-covalently associated subunits: a common α-subunit (92 amino acids) shared with LH, FSH, and TSH, and a hormone-specific β-subunit (145 amino acids) that confers receptor binding specificity and biological identity. The β-subunit of hCG is distinguished from that of LH by a unique 24-amino acid C-terminal extension (CTP) — a carboxy-terminal peptide not present in LH — that carries four O-linked oligosaccharide chains and is primarily responsible for hCG’s markedly extended plasma half-life compared to endogenous LH.

hCG acts as a high-affinity agonist at the luteinising hormone/chorionic gonadotropin receptor (LH-R / LHCGR) — a class A GPCR expressed predominantly in gonadal tissue: Leydig cells of the testis, granulosa and luteal cells of the ovary, and theca cells. LH-R engagement by hCG drives Gs/adenylyl cyclase/cAMP/PKA signalling as the primary pathway, with secondary activation of Gq/IP₃/calcium, ERK/MAPK, and PI3K/Akt cascades at higher receptor occupancy levels. In Leydig cells, this cAMP-driven signalling cascade activates the steroidogenic acute regulatory (StAR) protein, mobilising cholesterol into the mitochondrial inner membrane and initiating the testosterone biosynthesis pathway through CYP11A1 (cholesterol side-chain cleavage), CYP17A1 (17α-hydroxylase/17,20-lyase), and HSD17B3 (17β-hydroxysteroid dehydrogenase). In luteal cells, the equivalent cAMP/PKA cascade drives progesterone synthesis from cholesterol — the primary physiological function of placental hCG in maintaining the corpus luteum and sustaining early pregnancy.

The C-terminal peptide extension of the hCG β-subunit, and the extensive glycosylation of both subunits (accounting for approximately 30% of molecular weight), confer hCG with a plasma half-life of approximately 24–36 hours — compared to the 20–60 minute half-life of endogenous LH. This extended half-life makes hCG pharmacologically distinct from LH despite sharing the same receptor — producing a sustained, prolonged LH-R stimulus that differs fundamentally in its kinetics and downstream biological consequences from the brief pulsatile LH surges of endogenous gonadotropin signalling. This pharmacokinetic distinction is itself a research tool — enabling systematic comparison of sustained versus pulsatile LH-R activation and their differential effects on steroidogenesis, receptor regulation, and gonadal biology.

What Does hCG Do in Research?

In laboratory settings, hCG is studied across gonadotropin receptor pharmacology, Leydig cell and steroidogenesis biology, HPG axis regulation, ovarian biology, reproductive endocrinology, and comparative gonadotropin pharmacology. EU and European researchers working with hCG typically focus on:

LH-R pharmacology and gonadotropin receptor signalling — hCG is the most widely used experimental LH-R agonist in research — its extended half-life, commercial availability, and well-characterised receptor pharmacology making it the standard tool for LH-R activation studies. Research uses hCG to examine LH-R binding kinetics, Gs/cAMP/PKA primary signalling, secondary pathway activation (Gq, ERK/MAPK, PI3K/Akt), receptor internalisation and downregulation dynamics, and the dose-response relationship between LH-R occupancy and intracellular signal magnitude in gonadal cell lines and primary gonadal preparations.

Leydig cell biology and testicular steroidogenesis — hCG is the reference stimulus for Leydig cell activation and testosterone biosynthesis research — driving the complete steroidogenic cascade from cholesterol mobilisation through StAR to testosterone secretion through CYP11A1, CYP17A1, and HSD17B3. Studies use hCG to examine Leydig cell steroidogenic enzyme expression and activity, StAR-dependent cholesterol transport, the regulation of testosterone biosynthesis by LH-R/cAMP signalling, and the functional consequences of Leydig cell LH-R stimulation in isolated cell preparations, ex vivo testicular tissue, and in vivo pre-clinical models.

HPG axis regulation and gonadotropin biology research — The hypothalamic-pituitary-gonadal (HPG) axis integrates GnRH pulsatility, pituitary LH and FSH secretion, and gonadal steroid feedback into a tightly regulated neuroendocrine system. Studies use hCG as an exogenous LH-R agonist to probe the gonadal limb of the HPG axis — examining the steroidogenic and gonadal consequences of LH-R activation independently of upstream hypothalamic and pituitary regulation, and characterising the negative feedback of hCG-stimulated gonadal steroid production on hypothalamic GnRH and pituitary gonadotropin secretion.

LH-R desensitisation and downregulation research — Sustained or repeated LH-R stimulation by hCG produces a well-characterised desensitisation response — involving PKA-mediated uncoupling of the receptor from Gs, GRK-mediated receptor phosphorylation, β-arrestin recruitment, receptor internalisation, and transcriptional downregulation of LH-R gene expression in Leydig cells. hCG’s extended half-life makes it a particularly informative tool for studying LH-R desensitisation kinetics — driving a more sustained receptor activation than endogenous LH pulses and enabling systematic characterisation of the temporal sequence of desensitisation events and the conditions required for LH-R resensitisation.

Ovarian biology and luteal cell research — In the ovary, hCG drives luteinisation of granulosa cells, supports corpus luteum function through progesterone biosynthesis, and regulates the expression of ovarian steroidogenic enzymes. Studies use hCG in granulosa cell and luteal cell preparations to examine LH-R-driven progesterone synthesis, VEGF-mediated corpus luteum vascularisation, and the cellular biology of luteal cell LH-R responsiveness — contributing to understanding of luteal phase physiology and the mechanisms by which placental hCG rescues the corpus luteum from luteolysis in early pregnancy.

Steroidogenesis pathway research — hCG-driven cAMP/PKA activation in steroidogenic cells mobilises the complete steroidogenesis machinery — from StAR-dependent cholesterol transport through the sequential enzymatic conversion steps of the testosterone biosynthesis pathway. Studies examining individual steroidogenic enzyme function, StAR regulation, and the kinetics of the steroidogenic cascade use hCG as the reference LH-R stimulus — with its prolonged half-life providing a sustained cAMP signal that drives the complete steroidogenic response in isolated cell preparations, adrenal and gonadal tissue, and in vivo models.

cAMP/PKA signalling pathway research in steroidogenic cells — LH-R/Gs/adenylyl cyclase/cAMP is one of the most extensively studied GPCR signalling cascades in endocrinology — with Leydig and granulosa cells serving as primary model systems for cAMP-dependent steroidogenic signalling. Studies use hCG as the physiologically relevant cAMP-generating stimulus in these cell types to examine PKA substrate phosphorylation, CREB-mediated transcriptional regulation, PDE-mediated cAMP degradation kinetics, and the spatial organisation of cAMP signalling microdomains in gonadal steroidogenic cells.

GnRH analogue and HPG axis intervention research — Studies examining the consequences of GnRH agonist-driven LH suppression, GnRH antagonist administration, or other HPG axis interventions on gonadal function use hCG to distinguish between gonadal-level and upstream pituitary/hypothalamic contributions to altered steroidogenesis. By directly stimulating LH-R independently of endogenous LH, hCG enables researchers to probe residual Leydig cell steroidogenic capacity following HPG axis suppression — characterising the relative contributions of LH deficiency versus intrinsic Leydig cell dysfunction to hypogonadism phenotypes in pre-clinical models.

Placental biology and trophoblast research — Beyond its gonadal research applications, hCG is produced by and studied in trophoblast cell biology — where placental hCG production is examined as a marker of trophoblast differentiation, implantation biology, and early pregnancy maintenance. Studies in trophoblast cell lines and placental tissue use hCG as both a secreted product and a paracrine signalling molecule — examining the regulation of hCG gene expression, the processing of hCG precursor subunits, and the autocrine effects of trophoblast-derived hCG on placental LH-R-expressing cell populations.

Testosterone biosynthesis and androgen biology research — hCG-stimulated Leydig cell testosterone production provides a pharmacologically controlled, reproducible testosterone biosynthesis stimulus in pre-clinical research. Studies examining testosterone’s downstream anabolic, androgenic, and neuroendocrine effects use hCG administration as a means of generating controlled testicular testosterone output — enabling examination of testosterone’s tissue-level effects independently of variation in endogenous LH pulsatility, and providing a validated pre-clinical model of LH-R-driven androgen production.

Hypergonadotropism and LH-R mutation research — Activating mutations in LH-R that produce constitutive receptor signalling independent of ligand, and inactivating mutations that produce LH-R unresponsiveness, are studied using hCG challenge assays that probe LH-R functional status. Studies characterising wild-type versus mutant LH-R biology use hCG as the standardised receptor activation stimulus — enabling systematic comparison of cAMP generation, steroidogenic response magnitude, and receptor trafficking between normal and mutant LH-R variants in heterologous expression systems.

Comparative gonadotropin pharmacology — hCG versus LH — Despite sharing the same receptor, hCG and endogenous LH produce quantitatively and qualitatively distinct biological responses through their differing pharmacokinetic profiles and glycosylation patterns. Studies systematically comparing hCG and recombinant LH (r-LH) at the same LH-R examine how the duration of LH-R occupancy, the magnitude and kinetics of cAMP accumulation, and the pattern of downstream pathway activation differ between a sustained hCG stimulus and a brief LH pulse — contributing to understanding of how LH-R signal duration is decoded into distinct downstream biological outcomes.

All research applications are for in vitro and pre-clinical use only.

What Do Studies Say About hCG?

hCG has one of the most extensive research literatures of any gonadotropin — spanning reproductive endocrinology, gonadotropin receptor biology, steroidogenesis, and developmental biology — with foundational studies dating to its initial characterisation in the early twentieth century and a continuously active contemporary research literature.

LH-R pharmacology and signalling characterisation: Decades of studies using hCG as the primary LH-R agonist have comprehensively characterised LH-R signal transduction — establishing cAMP/PKA as the primary pathway, characterising the dose-dependent recruitment of secondary Gq, ERK/MAPK, and PI3K/Akt cascades, and mapping the structural determinants of LH-R/Gs coupling on both the receptor extracellular domain and the hCG β-subunit. Studies characterising LH-R signal bias — differential activation of cAMP versus β-arrestin pathways by different gonadotropin ligands — have used hCG alongside r-LH and engineered LH-R agonists to examine the structural basis of biased agonism at this receptor.

Leydig cell steroidogenesis and StAR regulation: hCG-stimulated Leydig cells have been the primary experimental model for characterising StAR protein function, regulation, and its essential role in cholesterol transport across the mitochondrial membrane as the rate-limiting step in steroidogenesis. Studies establishing StAR’s acute hormonal regulation by cAMP/PKA — and the downstream steroidogenic enzyme cascade from CYP11A1 through to testosterone — were performed predominantly using hCG as the LH-R activating stimulus in primary Leydig cell cultures and in vivo animal models.

LH-R desensitisation characterisation: Systematic studies of hCG-induced LH-R desensitisation documented the molecular sequence of events following sustained LH-R stimulation — GRK2/GRK3-mediated receptor phosphorylation, β-arrestin 1/2 recruitment, receptor internalisation via clathrin-coated pits, and the transcriptional suppression of LH-R mRNA in Leydig cells. These hCG desensitisation studies contributed foundational mechanistic data to the broader GPCR biology literature on agonist-driven receptor regulation — establishing Leydig cells and hCG as a primary model system for GPCR desensitisation research.

Comparative hCG versus LH biology: Studies systematically comparing the biological consequences of hCG versus endogenous LH at LH-R — using recombinant human LH as the comparator — documented that the sustained LH-R occupancy produced by hCG generates a larger cumulative cAMP signal, greater steroidogenic enzyme induction, and more profound LH-R desensitisation than equimolar LH doses with shorter receptor occupancy time. These comparative studies established that LH-R signal duration — not merely peak receptor occupancy — is a critical determinant of the qualitative and quantitative biological response to gonadotropin stimulation.

Corpus luteum rescue and progesterone biology: Studies examining hCG’s role in corpus luteum rescue during early pregnancy characterised the molecular mechanisms by which rising placental hCG concentrations sustain LH-R signalling in luteal cells as pituitary LH secretion declines — driving continued progesterone biosynthesis essential for endometrial maintenance and early pregnancy. These luteal biology studies established hCG as both a research tool and a physiological model for examining the consequences of sustained versus pulsatile LH-R stimulation on progesterone output and corpus luteum lifespan.

Glycosylation and pharmacokinetic studies: Studies examining the relationship between hCG glycosylation and its pharmacokinetic properties established that the O-linked oligosaccharides on the β-subunit CTP, and the N-linked oligosaccharides on both subunits, are primary determinants of the extended circulating half-life that distinguishes hCG from LH. These glycobiology studies — examining the consequences of deglycosylation on hCG half-life, receptor binding affinity, and in vivo biological activity — contributed to understanding of how glycosylation regulates glycoprotein hormone pharmacokinetics and provided the mechanistic basis for CTP-based half-life extension strategies applied to engineered LH and FSH analogues.

hCG vs Related Gonadotropin Axis Research Compounds

Compound	Class	Half-life	Receptor	Primary Signalling	Key Research Distinction
hCG	Placental glycoprotein gonadotropin	~24–36 hours	LH-R (LHCGR) — full agonist	Gs/cAMP/PKA	Reference LH-R agonist; sustained steroidogenic stimulus; Leydig cell research
Recombinant LH (r-LH)	Recombinant pituitary gonadotropin	~20–60 minutes	LH-R (LHCGR) — full agonist	Gs/cAMP/PKA	Short-acting LH-R comparator; pulsatile LH biology reference
Recombinant FSH (r-FSH)	Recombinant pituitary gonadotropin	~24–36 hours	FSH-R — full agonist	Gs/cAMP/PKA	FSH receptor pharmacology; granulosa/Sertoli cell biology
GnRH (native)	Hypothalamic decapeptide	<5 minutes	GnRH-R — full agonist	Gq/IP₃/calcium	Upstream HPG axis stimulus; pituitary gonadotropin release
Leuprolide (GnRH agonist)	Synthetic GnRH analogue	~3–4 hours	GnRH-R — sustained agonist	Gq → desensitisation	GnRH-R downregulation; LH/FSH suppression model
Cetrorelix / Ganirelix	GnRH antagonist	~12–20 hours	GnRH-R — competitive antagonist	Gq blockade	Acute GnRH-R blockade; rapid LH/FSH suppression
Kisspeptin-10	Hypothalamic neuropeptide	<10 minutes	Kiss1R (GPR54)	Gq/IP₃/calcium	GnRH pulse generation upstream of LH-R

Buying hCG in Europe — What’s Included

Every order of hCG dispatched to EU and European research institutions includes:

• Batch-Specific Certificate of Analysis (CoA)
• HPLC Chromatogram
• Mass Spectrometry Confirmation
• Sterility and Endotoxin Testing Reports
• Reconstitution Protocol
• Technical Research Support

Frequently Asked Questions — hCG EU

Can I Buy hCG in the EU and Europe?

Yes. We supply research-grade hCG with fast tracked dispatch to all EU member states and wider European destinations. All orders include full batch documentation. hCG is supplied strictly for laboratory research use only.

What is the Structural Difference Between hCG and LH, and Why Does It Matter for Research?

Both hCG and LH share an identical α-subunit and highly homologous β-subunits — binding the same LH-R with comparable affinity. The critical structural distinction is the 24-amino acid C-terminal peptide (CTP) extension unique to the hCG β-subunit, which carries four O-linked oligosaccharide chains absent from LH. This CTP-linked glycosylation is primarily responsible for hCG’s dramatically extended plasma half-life (~24–36 hours versus ~20–60 minutes for LH) — producing a sustained, prolonged LH-R occupancy that differs fundamentally from the brief pulsatile LH surges of endogenous gonadotropin signalling. For research, this means hCG and LH produce distinct temporal patterns of LH-R activation, cAMP accumulation, and downstream biological response — making the hCG versus r-LH comparison a tool for examining how LH-R signal duration determines biological outcome.

What is the Relationship Between hCG and Testosterone Biosynthesis?

hCG activates LH-R on testicular Leydig cells, driving Gs/cAMP/PKA signalling that acutely mobilises cholesterol into the mitochondrial inner membrane through StAR protein activation — the rate-limiting step in steroidogenesis. The mitochondrial enzyme CYP11A1 converts cholesterol to pregnenolone, which is subsequently processed through a sequence of enzymatic steps — including CYP17A1-mediated 17α-hydroxylation and lyase activity and HSD17B3-mediated reduction — to yield testosterone. The entire pathway from hCG binding to testosterone secretion is cAMP/PKA-dependent at the regulatory level, making hCG-stimulated Leydig cells the primary experimental model for characterising acute hormonal regulation of steroidogenesis, StAR function, and the steroidogenic enzyme cascade.

How Does hCG Differ From GnRH and GnRH Analogues in Research?

hCG and GnRH operate at distinct levels of the HPG axis. GnRH acts at the hypothalamic-pituitary interface — stimulating pituitary gonadotrophs to secrete LH and FSH through GnRH-R/Gq/IP₃/calcium signalling. hCG bypasses the hypothalamus and pituitary entirely, acting directly on gonadal LH-R to drive steroidogenesis. In research, this distinction enables mechanistic dissection of the HPG axis: GnRH analogues are used to manipulate pituitary gonadotropin secretion upstream, while hCG directly probes gonadal LH-R responsiveness and steroidogenic capacity downstream — independently of hypothalamic GnRH drive and pituitary LH output.

Why Does Prolonged hCG Stimulation Cause LH-R Downregulation?

Sustained LH-R occupancy by hCG — in contrast to the brief pulsatile LH surges of endogenous signalling — drives a well-characterised sequence of LH-R desensitisation events. Persistent cAMP/PKA activation leads to GRK2/3-mediated phosphorylation of the intracellular loops and C-terminal tail of LH-R, recruiting β-arrestin 1/2 and uncoupling the receptor from Gs. β-arrestin-mediated receptor internalisation through clathrin-coated pits removes LH-R from the cell surface, reducing receptor density available for further hCG binding. Prolonged stimulation additionally suppresses LH-R mRNA transcription through PKA-mediated regulatory mechanisms. Together, these desensitisation events explain the paradoxical reduction in testosterone output observed with sustained hCG administration — a phenomenon that has made hCG-induced LH-R desensitisation a primary model system for GPCR regulatory biology research.

What is the Difference Between hCG Research Applications and Clinical hCG Use?

Clinical hCG — used in reproductive medicine for ovulation triggering, luteal phase support, and treatment of hypogonadism — exploits the same LH-R agonism that underlies its research applications, but at doses, administration frequencies, and biological endpoints defined by therapeutic requirements. Research-grade hCG is supplied for use in controlled laboratory settings — in vitro Leydig cell steroidogenesis assays, gonadotropin receptor signalling studies, pre-clinical HPG axis models, and mechanistic biology research — where precise dose-response characterisation, receptor-level pharmacology, and signalling pathway dissection are the objectives. Research-grade hCG is not approved for human administration and is supplied exclusively for in vitro and pre-clinical laboratory research.

How Do I Reconstitute hCG for Laboratory Use?

Reconstitute with sterile water or phosphate-buffered saline (PBS) containing 0.1% BSA as carrier protein — BSA is recommended to minimise adsorption of the glycoprotein to vial and pipette surfaces at low working concentrations. Add solvent slowly down the vial wall and swirl gently — do not vortex, as shear forces can disrupt the non-covalent α/β subunit heterodimer. Prepare working stocks at the required concentration, aliquot into single-use volumes, and store at -80°C. Avoid repeated freeze-thaw cycles. As a glycoprotein hormone, hCG is more stable than unglycosylated peptides but should be handled with standard protein handling precautions to maintain biological activity.

How Quickly is hCG Delivered to Europe?

Delivery to EU and European destinations typically takes 3–7 working days via tracked international courier with packaging maintaining glycoprotein stability throughout transit.

Product Specifications

Parameter	Detail
Hormone	Human Chorionic Gonadotropin (hCG)
Structure	Heterodimeric glycoprotein — α-subunit (92 aa) + β-subunit (145 aa)
Unique Structural Feature	β-subunit 24-aa C-terminal peptide (CTP) — O-linked glycosylation; absent from LH
Molecular Weight	~36–40 kDa (protein backbone); ~57–60 kDa apparent (fully glycosylated)
Glycosylation	~30% molecular weight — N-linked (both subunits) + O-linked (β-CTP)
Primary Receptor	LH-R (LHCGR) — high-affinity full agonist
Primary Signalling	Gs/adenylyl cyclase/cAMP/PKA/StAR/steroidogenesis
Secondary Signalling	Gq/IP₃/calcium; ERK/MAPK; PI3K/Akt (higher receptor occupancy)
Plasma Half-life	~24–36 hours (vs ~20–60 min for endogenous LH)
Primary Research Interest	LH-R pharmacology, Leydig cell steroidogenesis, HPG axis biology, ovarian/luteal cell research, GPCR desensitisation
Purity	≥99%
Verification	HPLC & Mass Spectrometry
Form	Sterile Lyophilised Powder
Solubility	Sterile water or PBS + 0.1% BSA (carrier protein recommended)
Storage	-20°C, protected from light and moisture; avoid repeated freeze-thaw
Intended Use	Research use only

Research Disclaimer

Human Chorionic Gonadotropin (hCG) is supplied exclusively for legitimate scientific research conducted within licensed laboratory environments. This product is not approved for human consumption, self-administration, or any therapeutic, clinical, or veterinary application. It must be handled solely by qualified researchers in compliance with applicable EU regulations, national legislation, and institutional ethics guidelines. By purchasing, you confirm this compound will be used exclusively for approved in vitro or pre-clinical research purposes.